Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genetic Testing Solutions > Oncodona

Oncodona

Early risk detection of hereditary breast and ovarian cancer.

  • Technical Overview
  • Documentation
  • Scientific evidence
  • I’m not a health specialist
igenomix

Mutations in BRCA1 or BRCA2 genes are 20-fold higher in women with precocious breast cancer

POC Products of Conception

Mutations in BRCA1 and BRCA2 account for ≈ 5% of breast cancers and 10-15% of ovarian cancers.

SAT Sperm aneuploidy test

Oncodona test offers genetic counselling by experts

igenomix

Oncodona analyzes a panel of 21 genes

Interested in learning more?

Request information
Or Email us at supportspain@igenomix.com
Overview
  • Oncodona
  • Benefits
  • Indications

What is the Oncodona Test?

It is the most advanced genetic test for early identification of predisposition to inherited cancer.

Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.

The presence of a change or mutation in one of these genes assumes that the female carrier has an increased risk of developing breast and ovarian tumours, or other related cancers.

What is the procedure?

Why use Oncodona test?

  • The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
  • Carriers already diagnosed will be more likely to have another type of cancer.
  • A positive test result may also have important health implications for family members, and even future generations.

What genes are included in the Oncodona test?

 In addition to the BRCA1 and BRCA2 genes, the Oncodona test analyzes 19 more genes associated with risk of breast and ovarian cancer, which makes it a more complete test: 

Who should use Oncodona test?

  • Women diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. In these typesof patients Oncodona can find a mutation in up to 4% of women.
  • Women with a family member diagnosed with breast and ovarian cancer.
  • Women of general population without known increased risk.

Test limitations

  • It is reported that, in a particular case, the Oncodona test may not identify a mutation in the genes studied, even though a mutation may actually exist in one of the genes.
  • It is also reported that the Oncodona test can identify changes for which there is currently no medical consensus as to whether such changes pose an increased risk of developing cancer.
  • The Oncodona test does not include all genes for which the medical literature indicates a possible association with breast and/or ovarian cancer.
Documentation
  • Specialists documents

Brochure

Download
Scientific evidence

Relevant related studies:

Malone et al. Cancer Res 2006;66(16):8297-8308

JAMA Oncol. 2015;1(7):943-951. doi:10.1001/jamaoncol. 2015.2690

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.

If you're a little lost with this technical information...

Can we help you?

I’m not a health specialist

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix

Learn about genetics

NEW COURSES AVAILABLE:

Non Invasive PGS, Maria Vera

Sociis natoque penatibus et magnis dis parturient
More courses

Other services

CGT Carrier Genetic Test

CGT

Determines the risk of having a child with a genetic disease

More information
PGT-M Preimplantation Genetic Testing

PGT-M

Prevents the transmission of single gene disorders

More information
PGT-A Preimplantation Genetic Testing

PGT-A

Chromosomally normal
embryos selection

More information

Igenomix is in the media

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information